SCHEMBL4071983

SCHEMBL4071983

O=C(O)c1nc(Br)c2cccnc2c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.56
HSP90AA1 P07900 4/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
TP53 P04637 3/20 0.49
HTT P42858 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
TDP1 Q9NUW8 3/20 0.49
USP2 O75604 2/20 0.49
ALDH1A1 P00352 6/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
KDM4A O75164 2/20 0.46
EGLN1 Q9GZT9 2/20 0.46
KDM6B O15054 1/20 0.46
KDM6A O15550 1/20 0.46
TET3 O43151 1/20 0.46
KDM4B O94953 1/20 0.46
KDM5C P41229 1/20 0.46
KDM4D Q6B0I6 1/20 0.46
TET2 Q6N021 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7258267 0.85 KDM4E (0.53) KDM4EHSP90AA1MEN1KMT2ATP53
SCHEMBL966397 0.82 KDM4E (0.51) KDM4EHSP90AA1MEN1KMT2ATP53
SCHEMBL6646416 0.81 KDM4E (0.49) KDM4EHSP90AA1MEN1KMT2ATP53
SCHEMBL966265 0.80 CDK9 (0.42) KDM4EMEN1KMT2ASMN1; SMN2TDP1
SCHEMBL14287857 0.79 CALCA (0.45) KDM4EHSP90AA1MEN1KMT2ATP53
SCHEMBL523579 0.78 RNASEH1 (0.46) KDM4EHSP90AA1MEN1KMT2AHTT
SCHEMBL27879292 0.78 KDM4E (0.49) KDM4EHSP90AA1MEN1KMT2ATP53
SCHEMBL7258791 0.77 KDM4E (0.45) KDM4EHSP90AA1MEN1KMT2ATP53
SCHEMBL4061987 0.75 MAPT (0.44) KDM4EMEN1KMT2AHTTTDP1
SCHEMBL4059851 0.75 CALCA (0.63) KMT2AL3MBTL1EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101684119-B 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, preparing method, composite and application thereof SHANGHAI INST MATERIA MEDICA 2012-11-28 CN disclosed
CN-101684119-A 5,8-disubstituted-1,6-quinazoline-7-amidocarbonylation compound, preparing method, composite and application thereof SHANGHAI INST MATERIA MEDICA 2010-03-31 CN disclosed
EP-1664046-B1 AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2009-06-17 EP disclosed
US-7462721-B2 Aza-quinolinol phosphonate integrase inhibitor compounds GILEAD SCIENCES, INC. (US) 2008-12-09 US disclosed
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds GILEAD SCIENCES, INC. 2008-03-27 US disclosed
US-7323460-B2 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-01-29 US disclosed
US-7323460-B2 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-01-29 US disclosed
US-20070185007-A1 Aza-quinolinol phosphonate integrase inhibitor compounds JIN HAOLUN 2007-08-09 US disclosed
EP-1742642-A2 PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2007-01-17 EP disclosed
EP-1664046-A1 AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2006-06-07 EP disclosed
US-20060116356-A1 Phosphonate analogs of HIV integrase inhibitor compounds GILEAD SCIENCES, INC. 2006-06-01 US disclosed
WO-2005117904-A2 PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-12-15 WO disclosed
US-20050137199-A1 Inhibition of HiV integrase compounds GILEAD SCIENCES, INC. 2005-06-23 US disclosed
WO-2005028478-A1 AZA-QUINOLINOL PHOSPHONATE INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-03-31 WO disclosed
WO-2003077857-A2 N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2003-09-25 WO disclosed
EP-1326865-A2 AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2003-07-16 EP disclosed
WO-2002030930-A2 AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137199-A1 Inhibition of HiV integrase compounds CDKL5, CDKL1, CDKL3 KDM4E 354/4885HSP90AA1 4725/4885MEN1 4204/4885
US-20060116356-A1 Phosphonate analogs of HIV integrase inhibitor compounds TYMP, PNP, PIKFYVE KDM4E 1618/4885HSP90AA1 2805/4885MEN1 4347/4885
US-20070185007-A1 Aza-quinolinol phosphonate integrase inhibitor compounds CDKL5, CDKL1, CDKL3 KDM4E 303/4885HSP90AA1 4766/4885MEN1 3765/4885
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds TYMP, PNP, PIKFYVE KDM4E 1618/4885HSP90AA1 2805/4885MEN1 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.